PE PREMIER CHINA CLINICAL TRIAL

PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02230254

Enrollment

101

Registered

2014-09-03

Start date

2014-04-09

Completion date

2015-07-31

Last updated

2022-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

Coronary Artery Disease

Brief summary

PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)

Detailed description

To evaluate clinical and peri-procedural angiographic outcomes for the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) ≤34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate)

Interventions

DEVICEPercutaneous coronary intervention PROMUS PREMIER

PROMUS PREMIER

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Clinical Inclusion (CI) Criteria CI1. Subject must be at least 18 -75 years of age CI2. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed CI3. Subject is eligible for percutaneous coronary intervention (PCI) CI4. Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia CI5. Subject is an acceptable candidate for coronary artery bypass grafting (CABG) CI6. Subject is willing to comply with all protocol-required follow-up evaluation CI7. Subject has a left ventricular ejection fraction (LVEF) \>30% as measured within 60 days prior to enrollment * Angiographic Inclusion (AI) Criteria (visual estimate) AI1. Target lesion(s) must be located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥2.25 mm and ≤4.0 mm AI2. Target lesion(s) length must be ≤34 mm ( Target lesion(s) length must be ≤28 mm for reference vessel diameter (RVD) = 2.25 mm Target lesion(s)) (by visual estimate) AI3. Target lesion(s) must have visually estimated stenosis ≥50% and \<100% with thrombolysis in Myocardial Infarction (TIMI) flow \>1 and one of the following (stenosis ≥70%, abnormal fractional flow reserve (FFR), abnormal stress test or imaging stress test, or elevated biomarkers) prior to procedure AI4. Coronary anatomy is likely to allow delivery of a study device to the target lesions(s) AI5. The first lesion treated must be successfully pre-dilated/pretreated Note: Successful pre-dilatation/pretreatment refers to dilatation with a balloon catheter of appropriate length and diameter, or pretreatment with/or rotational coronary atherectomy, or cutting/scoring balloon with no greater than 50% residual stenosis and no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C.

Exclusion criteria

* Clinical Exclusion (CE) Criteria CE1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with Acute MI (include STEMI and Non- STEMI ) within 1 week CE2. Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina CE3. Subject has received an organ transplant or is on a waiting list for an organ transplant CE4. Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure CE5. Planned PCI (including staged procedures) or CABG after the index procedure CE6. Subject previously treated at any time with intravascular brachytherapy CE7. Subject has a known allergy to contrast (that cannot be adequately pre-medicated) and/or the trial stent system or protocol-required concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related compounds, polymer or individual components, Clopidogrel , or aspirin) CE8. Subject has one of the following (as assessed prior to the index procedure): * Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 12 months * Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.) * Planned procedure that may cause non-compliance with the protocol or confound data interpretation CE9. Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin, coumadin) for indications other than acute coronary syndrome CE10. Subject with out of range complete blood count (CBC) values that are determined by the study physician to be clinically significant. CE11. Subject has documented or suspected liver disease, including laboratory evidence of hepatitis CE12. Subject is on dialysis or has baseline serum creatinine level \>2.0 mg/dL (177µmol/L) CE13. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions CE14. Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months CE15. Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding CE16. Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) at the time of the index procedure CE17. Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint CE18. Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure CE19. Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure) CE20. Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential) CE21.Target vessel has been treated with any type of PCI (e.g., balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to the index procedure * Angiographic Exclusion (AE) Criteria (visual estimate) AE1. Planned treatment of more than 3 lesions. AE2. Planned treatment of lesions in more than 2 major epicardial vessels AE3. Planned treatment of a single lesion with more than 1 stent AE4. Subject has 2 target lesions in the same vessel that are separated by less than 20 mm (by visual estimate) AE5. Target lesion(s) is located in the left main AE6. Target lesion(s) is located within 3 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate. AE7. Target lesion(s) is located within a saphenous vein graft or an arterial graft AE8. Target lesion(s) will be accessed via a saphenous vein graft or arterial graft AE9. Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing AE10. Target lesion(s) treated during the index procedure that involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent) AE11. Target lesion(s) is restenotic from a previous stent implantation or study stent would overlap with a previous stent AE12. Subject has unprotected left main coronary artery disease (\>50% diameter stenosis) AE13. Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent, cutting balloon atherectomy) within 24 hours prior to the index procedure AE14. Thrombus, or possible thrombus, present in the target vessel (by visual estimate) AE15. Excessive tortuosity proximal to or within the lesion AE16. Excessive angulation proximal to or within the lesion AE17. Target lesion and/or the target vessel proximal to the target lesion is moderately to severely calcified by visual estimate AE18. Involves a side branch ≥2.0 mm in diameter by visual estimate or a side branch \<2.0 mm in diameter by visual estimate which requires treatment

Design outcomes

Primary

Measure	Time frame	Description
Technical Success Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day	Technical success rate, defined as successful delivery and deployment of the study stent to the target lesion, without balloon rupture or stent embolization, and post-procedure diameter stenosis of \<30% assessed in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician

Secondary

Measure	Time frame	Description
Target Lesion Failure (TLF) Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
Target Vessel Revascularization (TVR) Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6month and 12months	—
Target Vessel Failure (TVF) Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
Myocardial Infarction (MI, Q-wave and Non-Q-wave) Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
Cardiac Death Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
Non-cardiac Death Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
All Death Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
Cardiac Death or MI Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
Target Lesion Revascularization (TLR) Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
All Death/MI/TVR Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
Stent Thrombosis Rate (by Academic Research Consortium [ARC] Definitions)	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
Clinical Procedural Success Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
In-stent and In-segment Percent Diameter Stenosis (%DS)	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
In-stent and In-segment Minimum Lumen Diameter (MLD)	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
Acute Gain	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	as measured by angiographic core lab, change from baseline for target lesions
Longitudinal Stent Deformation (LSD) Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—
All Death or MI Rate	Participants will be followed for the duration of hospital stay, an expected average of 1 day, at 30 days, 6months and 12months	—

Participant flow

Pre-assignment details

Total Started: 101

Participants by arm

Arm	Count
PROMUS POREMIER Stent Single-arm treatment group receiving interventional PROMUS PRIMIER study stent Percutaneous coronary intervention PROMUS PREMIER: PROMUS PREMIER	101
Total	101

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Lost to Follow-up	3

Baseline characteristics

Characteristic	PROMUS POREMIER Stent
Age, Continuous	61.47 Year STANDARD_DEVIATION 9.27
Sex: Female, Male Female	24 Participants
Sex: Female, Male Male	77 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 101
other Total, other adverse events	13 / 101
serious Total, serious adverse events	8 / 101

Outcome results

Primary

Technical Success Rate

Technical success rate, defined as successful delivery and deployment of the study stent to the target lesion, without balloon rupture or stent embolization, and post-procedure diameter stenosis of \<30% assessed in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician

Time frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day

Arm	Measure	Value (NUMBER)
PROMUS POREMIER Stent	Technical Success Rate	99.1 percentage of participants

Secondary